Identification of cellular senescence-associated genes for predicting the diagnosis, prognosis and immunotherapy response in lung adenocarcinoma via a 113-combination machine learning framework

利用113种组合的机器学习框架,识别与细胞衰老相关的基因,以预测肺腺癌的诊断、预后和免疫治疗反应。

阅读:1

Abstract

BACKGROUND: Lung adenocarcinoma (LUAD) is a prevalent malignant tumor of the respiratory system, with high incidence and mortality rates. Cellular senescence (CS) widely affects the tumor microenvironment (TME) and tumor growth, and is related to the invasion and immune escape of tumor cells. This study aims to develop a robust CS-related signature of LUAD. METHODS: Using the GSE140797, GSE42458, GSE75037, and GSE85841 datasets, in combination with cellular senescence databases, 75 LUAD CS-related differentially expressed genes (LUAD-CSDEGs) were identified through the weighted gene co-expression network analysis (WGCNA) method. Subsequently, we developed a novel machine learning framework that incorporated 12 machine learning algorithms and their 113 combinations to construct a LUAD CS-related signature (LUAD-CSRS), which were assessed in both training and validation cohorts. A LUAD-CSRS-integrated nomogram was constructed to provide a quantitative tool for predicting prognosis in clinical practice. Finally, the difference of immune infiltration and response to immunotherapy in patients with high and low risk of LUAD were evaluated. RESULTS: Based on a 113-combination machine learning framework, we finally identified a LUAD-CSRS containing eight genes: RECQL4, TIMP1, ANLN, SFN, MDK, KIF2C, AGR2, ITGB4. We also confirmed that it was significantly associated with survival, immune cell infiltration, prognosis, and response to immunotherapy in LUAD patients. Additionally, we found it is related to the activation of immune responses and may be involved in regulating the balance between immune cells in the TME. CONCLUSION: In summary, our study constructed a novel LUAD-CSRS, which is not only expected to be a powerful tool for assisting diagnosis and prognosis evaluation of LUAD, but also may provide guidance for personalized immunotherapy programs.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。